BARBATO, SIMONA
BARBATO, SIMONA
DIBINEM - DIPARTIMENTO DI SCIENZE BIOMEDICHE E NEUROMOTORIE
Assegnisti
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing
2025 Puppi, M.; Sacchetti, I.; Mancuso, K.; Tacchetti, P.; Pantani, L.; Rizzello, I.; Iezza, M.; Talarico, M.; Manzato, E.; Masci, S.; Restuccia, R.; Barbato, S.; Armuzzi, S.; Taurisano, B.; Vigliotta, I.; Zamagni, E.; Mancuso, K.
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma
2025 Talarico, Marco; Vischini, Gisella; Barbato, Simona; Restuccia, Roberta; Masci, Simone; Sacchetti, Ilaria; Manzato, Enrica; Ghibellini, Stefano; Puppi, Michele; Iezza, Miriam; Rizzello, Ilaria; Pantani, Lucia; Tacchetti, Paola; Borsi, Enrica; Solli, Vincenza; Terragna, Carolina; Agostinelli, Claudio; La Manna, Gaetano; Cavo, Michele; Zamagni, Elena; Mancuso, Katia
Correction: Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma
2025 Mancuso, K.; Barbato, S.; Raimondo, F. D.; Gay, F.; Musto, P.; Offidani, M.; Petrucci, M. T.; Zamagni, E.; Zambello, R.; Cavo, M.
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma
2025 Talarico, M.; Barbato, S.; Cattabriga, A.; Sacchetti, I.; Manzato, E.; Restuccia, R.; Masci, S.; Bigi, F.; Puppi, M.; Iezza, M.; Rizzello, I.; Mancuso, K.; Pantani, L.; Tacchetti, P.; Nanni, C.; Cavo, M.; Zamagni, E.
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?
2025 Talarico, M.; Barbato, S.; Maisnar, V.; Delimpasi, S.; Puppi, M.; Rizzello, I.; Pantani, L.; Tacchetti, P.; Martello, M.; Vigliotta, I.; Terragna, C.; Cavo, M.; Zamagni, E.; Mancuso, K.
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma
2025 Mancuso, K.; Barbato, S.; Di Raimondo, F.; Gay, F.; Musto, P.; Offidani, M.; Petrucci, M. T.; Zamagni, E.; Zambello, R.; Cavo, M.
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
2025 Mancuso, Katia; Barbato, Simona; Talarico, Marco; Tacchetti, Paola; Zamagni, Elena; Cavo, Michele
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS
2025 Mancuso, K.; Talarico, M.; Manzato, E.; Barbato, S.; Tacchetti, P.; Zamagni, E.; Cavo, M.
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home
2025 Bigi, F.; Fiacchini, M.; Restuccia, R.; Masci, S.; Mazzocchetti, G.; Talarico, M.; Puppi, M.; Sacchetti, I.; Manzato, E.; Iezza, M.; Mancuso, K.; Sartor, C.; Pantani, L.; Tacchetti, P.; Alatif, R. A.; Pastore, E.; Barbato, S.; Cavo, M.; Zamagni, E.; Rizzello, I.
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
2024 Tacchetti, P.; Talarico, M.; Barbato, S.; Pantani, L.; Mancuso, K.; Rizzello, I.; Zamagni, E.; Cavo, M.
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
2024 Tacchetti, Paola; Barbato, Simona; Mancuso, Katia; Zamagni, Elena; Cavo, Michele
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study
2024 Mancuso, K.; Mina, R.; Rocchi, S.; Antonioli, E.; Petrucci, M. T.; Fazio, F.; Gozzetti, A.; Salvini, M.; Cartia, C. S.; Bertuglia, G.; Patriarca, F.; Dalla Palma, A. B.; Barbato, S.; De Cicco, G.; Bigi, F.; Favero, E.; Tacchetti, P.; Pantani, L.; Rizzello, I.; Puppi, M.; Talarico, M.; Solli, V.; Kanapari, A.; Cavo, M.; Zamagni, E.
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review
2024 Bigi F.; Manzato E.; Barbato S.; Talarico M.; Puppi M.; Masci S.; Sacchetti I.; Restuccia R.; Iezza M.; Rizzello I.; Sartor C.; Mancuso K.; Pantani L.; Tacchetti P.; Cavo M.; Zamagni E.
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma
2024 Bigi, F.; Tacchetti, P.; Giorgi, A.; Mazzocchetti, G.; Solli, V.; Barbato, S.; Sinigaglia, B.; Campanini, E.; Favero, E.; Talarico, M.; Puppi, M.; Rizzello, I.; Rocchi, S.; Mancuso, K.; Pantani, L.; Cavo, M.; Zamagni, E.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
2023 Zamagni E.; Oliva S.; Gay F.; Capra A.; Rota-Scalabrini D.; D'Agostino M.; Belotti A.; Galli M.; Racca M.; Zambello R.; Gamberi B.; Albano D.; Bertamini L.; Versari A.; Grasso M.; Sgherza N.; Priola C.; Fioritoni F.; Patriarca F.; De Cicco G.; Villanova T.; Pascarella A.; Zucchetta P.; Tacchetti P.; Fanti S.; Mancuso K.; Barbato S.; Boccadoro M.; Musto P.; Cavo M.; Nanni C.
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma
2023 Mancuso K.; Zamagni E.; Solli V.; Gabrielli L.; Leone M.; Pantani L.; Rocchi S.; Rizzello I.; Tacchetti P.; Ghibellini S.; Favero E.; Ursi M.; Talarico M.; Barbato S.; Kanapari A.; Bigi F.; Puppi M.; Terragna C.; Borsi E.; Martello M.; Poletti A.; Scata A.; Nepoti G.; Ruffini B.; Lazzarotto T.; Cavo M.
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
2022 Martello M.; Poletti A.; Borsi E.; Solli V.; Dozza L.; Barbato S.; Zamagni E.; Tacchetti P.; Pantani L.; Mancuso K.; Vigliotta I.; Rizzello I.; Rocchi S.; Armuzzi S.; Testoni N.; Marzocchi G.; Martinelli G.; Cavo M.; Terragna C.
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
2022 Tacchetti P.; Rocchi S.; Zamagni E.; Barbato S.; Rizzello I.; De Cicco G.; Pantani L.; Mancuso K.; Fusco A.; Dozza L.; Ursi M.; Favero E.; Terragna C.; Testoni N.; Cavo M.
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients
2021 Tacchetti P.; Rocchi S.; Barbato S.; Zamagni E.; Pantani L.; Mancuso K.; Rizzello I.; Cavo M.
How I Treat High-risk Multiple Myeloma
2021 Zamagni, Elena; Barbato, Simona; Cavo, Michele
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing | Puppi, M.; Sacchetti, I.; Mancuso, K.; Tacchetti, P.; Pantani, L.; Rizzello, I.; Iezza, M.; Talar...ico, M.; Manzato, E.; Masci, S.; Restuccia, R.; Barbato, S.; Armuzzi, S.; Taurisano, B.; Vigliotta, I.; Zamagni, E.; Mancuso, K. | 2025-01-01 | MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES | - | 1.01 Articolo in rivista | Puppi+PDF.pdf |
| Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma | Talarico, Marco; Vischini, Gisella; Barbato, Simona; Restuccia, Roberta; Masci, Simone; Sacchetti..., Ilaria; Manzato, Enrica; Ghibellini, Stefano; Puppi, Michele; Iezza, Miriam; Rizzello, Ilaria; Pantani, Lucia; Tacchetti, Paola; Borsi, Enrica; Solli, Vincenza; Terragna, Carolina; Agostinelli, Claudio; La Manna, Gaetano; Cavo, Michele; Zamagni, Elena; Mancuso, Katia | 2025-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | fonc-15-1672690.pdf |
| Correction: Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma | Mancuso, K.; Barbato, S.; Raimondo, F. D.; Gay, F.; Musto, P.; Offidani, M.; Petrucci, M. T.; Zam...agni, E.; Zambello, R.; Cavo, M. | 2025-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-17-02555.pdf |
| Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma | Talarico, M.; Barbato, S.; Cattabriga, A.; Sacchetti, I.; Manzato, E.; Restuccia, R.; Masci, S.; ...Bigi, F.; Puppi, M.; Iezza, M.; Rizzello, I.; Mancuso, K.; Pantani, L.; Tacchetti, P.; Nanni, C.; Cavo, M.; Zamagni, E. | 2025-01-01 | JOURNAL OF BONE ONCOLOGY | - | 1.01 Articolo in rivista | 1-s2.0-S2212137425000107-main.pdf |
| Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? | Talarico, M.; Barbato, S.; Maisnar, V.; Delimpasi, S.; Puppi, M.; Rizzello, I.; Pantani, L.; Tacc...hetti, P.; Martello, M.; Vigliotta, I.; Terragna, C.; Cavo, M.; Zamagni, E.; Mancuso, K. | 2025-01-01 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | s00432-025-06326-3.pdf |
| Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma | Mancuso, K.; Barbato, S.; Di Raimondo, F.; Gay, F.; Musto, P.; Offidani, M.; Petrucci, M. T.; Zam...agni, E.; Zambello, R.; Cavo, M. | 2025-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-17-01168-v2.pdf |
| Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma | Mancuso, Katia; Barbato, Simona; Talarico, Marco; Tacchetti, Paola; Zamagni, Elena; Cavo, Michele | 2025-01-01 | EXPERT OPINION ON BIOLOGICAL THERAPY | - | 1.01 Articolo in rivista | Idecabtagene vicleucel ide-cel for the treatment of triple-class exposed relapsed and refractory multiple myeloma.pdf |
| T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS | Mancuso, K.; Talarico, M.; Manzato, E.; Barbato, S.; Tacchetti, P.; Zamagni, E.; Cavo, M. | 2025-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-17-01514.pdf |
| Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home | Bigi, F.; Fiacchini, M.; Restuccia, R.; Masci, S.; Mazzocchetti, G.; Talarico, M.; Puppi, M.; Sac...chetti, I.; Manzato, E.; Iezza, M.; Mancuso, K.; Sartor, C.; Pantani, L.; Tacchetti, P.; Alatif, R. A.; Pastore, E.; Barbato, S.; Cavo, M.; Zamagni, E.; Rizzello, I. | 2025-01-01 | CLINICAL AND EXPERIMENTAL MEDICINE | - | 1.01 Articolo in rivista | s10238-025-01683-2.pdf; 10238_2025_1683_MOESM1_ESM.docx |
| Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma | Tacchetti, P.; Talarico, M.; Barbato, S.; Pantani, L.; Mancuso, K.; Rizzello, I.; Zamagni, E.; Ca...vo, M. | 2024-01-01 | EXPERT REVIEW OF ANTICANCER THERAPY | - | 1.01 Articolo in rivista | - |
| Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma | Tacchetti, Paola; Barbato, Simona; Mancuso, Katia; Zamagni, Elena; Cavo, Michele | 2024-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-16-02337.pdf |
| Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study | Mancuso, K.; Mina, R.; Rocchi, S.; Antonioli, E.; Petrucci, M. T.; Fazio, F.; Gozzetti, A.; Salvi...ni, M.; Cartia, C. S.; Bertuglia, G.; Patriarca, F.; Dalla Palma, A. B.; Barbato, S.; De Cicco, G.; Bigi, F.; Favero, E.; Tacchetti, P.; Pantani, L.; Rizzello, I.; Puppi, M.; Talarico, M.; Solli, V.; Kanapari, A.; Cavo, M.; Zamagni, E. | 2024-01-01 | CANCER MEDICINE | - | 1.01 Articolo in rivista | Cancer Medicine - 2024 - Mancuso - Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal.pdf; cam470266-sup-0001-datas1.docx |
| Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review | Bigi F.; Manzato E.; Barbato S.; Talarico M.; Puppi M.; Masci S.; Sacchetti I.; Restuccia R.; Iez...za M.; Rizzello I.; Sartor C.; Mancuso K.; Pantani L.; Tacchetti P.; Cavo M.; Zamagni E. | 2024-01-01 | PHARMACEUTICALS | - | 1.01 Articolo in rivista | pharmaceuticals-17-00944.pdf; pharmaceuticals-17-00944-s001.zip |
| Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma | Bigi, F.; Tacchetti, P.; Giorgi, A.; Mazzocchetti, G.; Solli, V.; Barbato, S.; Sinigaglia, B.; Ca...mpanini, E.; Favero, E.; Talarico, M.; Puppi, M.; Rizzello, I.; Rocchi, S.; Mancuso, K.; Pantani, L.; Cavo, M.; Zamagni, E. | 2024-01-01 | FRONTIERS IN HEMATOLOGY | - | 1.01 Articolo in rivista | frhem-2-1386973.pdf; Data Sheet 1.docx |
| Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial | Zamagni E.; Oliva S.; Gay F.; Capra A.; Rota-Scalabrini D.; D'Agostino M.; Belotti A.; Galli M.; ...Racca M.; Zambello R.; Gamberi B.; Albano D.; Bertamini L.; Versari A.; Grasso M.; Sgherza N.; Priola C.; Fioritoni F.; Patriarca F.; De Cicco G.; Villanova T.; Pascarella A.; Zucchetta P.; Tacchetti P.; Fanti S.; Mancuso K.; Barbato S.; Boccadoro M.; Musto P.; Cavo M.; Nanni C. | 2023-01-01 | ECLINICALMEDICINE | - | 1.01 Articolo in rivista | PIIS2589537023001943.pdf; mmc1 (1).pdf |
| Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma | Mancuso K.; Zamagni E.; Solli V.; Gabrielli L.; Leone M.; Pantani L.; Rocchi S.; Rizzello I.; Tac...chetti P.; Ghibellini S.; Favero E.; Ursi M.; Talarico M.; Barbato S.; Kanapari A.; Bigi F.; Puppi M.; Terragna C.; Borsi E.; Martello M.; Poletti A.; Scata A.; Nepoti G.; Ruffini B.; Lazzarotto T.; Cavo M. | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | 2023 Mancuso K ematologia fonc-13-1208741.pdf; Data Sheet 1.docx |
| Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma | Martello M.; Poletti A.; Borsi E.; Solli V.; Dozza L.; Barbato S.; Zamagni E.; Tacchetti P.; Pant...ani L.; Mancuso K.; Vigliotta I.; Rizzello I.; Rocchi S.; Armuzzi S.; Testoni N.; Marzocchi G.; Martinelli G.; Cavo M.; Terragna C. | 2022-01-01 | BLOOD CANCER JOURNAL | - | 1.01 Articolo in rivista | s41408-022-00610-y.pdf; 41408_2022_610_MOESM1_ESM (1).docx |
| Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma | Tacchetti P.; Rocchi S.; Zamagni E.; Barbato S.; Rizzello I.; De Cicco G.; Pantani L.; Mancuso K....; Fusco A.; Dozza L.; Ursi M.; Favero E.; Terragna C.; Testoni N.; Cavo M. | 2022-01-01 | AMERICAN JOURNAL OF HEMATOLOGY | - | 1.01 Articolo in rivista | American J Hematol - 2022 - Tacchetti - Role of serum‐free light chain assay for defining response and progression in.pdf |
| Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients | Tacchetti P.; Rocchi S.; Barbato S.; Zamagni E.; Pantani L.; Mancuso K.; Rizzello I.; Cavo M. | 2021-01-01 | EXPERT REVIEW OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| How I Treat High-risk Multiple Myeloma | Zamagni, Elena; Barbato, Simona; Cavo, Michele | 2021-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |